Get Your Personalized Supplement StackSupplement Stack Quiz

Piperlongumine

Q: Is piperlongumine safe for human use?

Clinical safety data for piperlongumine in humans are lacking. Its use should be approached with caution and is currently limited to research settings due to insufficient evidence on its safety profile.

Q: How quickly does piperlongumine work?

In vitro effects on cells can be observed within 24 hours. In vivo, effects on tumor growth in animal models typically require several weeks of consistent administration to become apparent.

Q: Can piperlongumine be used as a cancer treatment?

While piperlongumine shows promise in preclinical cancer models, it is not approved or validated for clinical cancer therapy in humans. Further research and clinical trials are needed before it can be considered a treatment.

Q: Does piperlongumine have other health benefits?

Beyond its anticancer potential, preclinical studies suggest potential vascular benefits through the improvement of endothelial progenitor cell function. However, these findings require further investigation and human validation.

Also known as: PL, piplartine, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone, Piperlongumine

Overview

Piperlongumine is a natural alkaloid isolated from the long pepper plant (Piper longum), a plant traditionally used in herbal medicine. It is primarily investigated for its potential anticancer properties, with emerging evidence suggesting effects on vascular and metabolic dysfunction. Key characteristics include its ability to selectively induce oxidative stress in cancer cells and modulate cellular stress pathways. Research on piperlongumine is in a moderate stage of maturity, with numerous preclinical studies and mechanistic investigations. However, clinical trials are limited, and the majority of evidence comes from in vitro and animal studies. While systematic reviews on its anticancer potential have been published, robust clinical trial data in humans are scarce, indicating that its therapeutic application is still largely theoretical.

Benefits

Piperlongumine exhibits significant anticancer activity, primarily by inhibiting tumor growth through the induction of endoplasmic reticulum (ER) stress and modulation of tumor-associated macrophage polarization. Preclinical studies, particularly in lung cancer models, have shown statistically significant tumor volume reduction (p < 0.05). Beyond its anticancer effects, piperlongumine also demonstrates potential vascular protective benefits. It has been shown to improve endothelial progenitor cell (EPC) function, which is often impaired by high-fat diet-induced metabolic stress, thereby enhancing angiogenesis and reducing thrombospondin expression. These effects suggest a role in improving vascular health. While effect sizes in preclinical models are significant, human data are lacking, and clinical relevance remains to be established. The benefits have been observed over several weeks in animal models for tumor growth and within 24 hours for EPC function in vitro.

How it works

Piperlongumine's primary mechanism of action involves inducing endoplasmic reticulum (ER) stress, which leads to apoptosis (programmed cell death) specifically in cancer cells. It also inhibits the polarization of M2-type macrophages, which are known to promote tumor progression. Piperlongumine modulates oxidative stress pathways by selectively increasing reactive oxygen species (ROS) levels in cancer cells, contributing to their demise. Its molecular targets include various stress response proteins and signaling pathways crucial for cell survival and immune modulation. Additionally, it enhances angiogenic potential by rescuing endothelial progenitor cell (EPC) function, possibly through the downregulation of anti-angiogenic factors like thrombospondin-1 and -2. Absorption and bioavailability data for piperlongumine are limited, but as a natural alkaloid, it is likely to have moderate bioavailability and undergo metabolism by liver enzymes.

Side effects

The overall safety of piperlongumine in humans is not well established due to the limited clinical data available. Preclinical studies have generally not reported significant toxicity at effective doses in animal models. However, common side effects in humans are not well documented. Given its mechanism of inducing oxidative stress, there is a theoretical concern that high doses could potentially affect normal cells, although this has not been widely observed in preclinical settings. Information regarding drug interactions and contraindications for piperlongumine is currently unknown. Furthermore, its safety in special populations, such as pregnant women, children, or individuals with liver or kidney impairment, has not been studied, and caution is advised. Due to the lack of comprehensive human safety data, piperlongumine should be approached with caution and its use limited to research contexts.

Dosage

Currently, there are no established dosing guidelines for piperlongumine in humans. Preclinical studies have utilized concentrations in the micromolar range for cell culture experiments (e.g., 0.1–1.0 μM) and effective doses in animal models. However, the optimal dosage and the maximum safe dose for human consumption remain unknown. Timing considerations for administration are based on experimental protocols, such as daily dosing in animal studies, but these do not translate directly to human use. Form-specific recommendations and factors influencing absorption and bioavailability have not been fully characterized. There are no known required cofactors for its activity. Due to the absence of human clinical data, any use of piperlongumine outside of controlled research settings is not recommended.

FAQs

Is piperlongumine safe for human use?

Clinical safety data for piperlongumine in humans are lacking. Its use should be approached with caution and is currently limited to research settings due to insufficient evidence on its safety profile.

How quickly does piperlongumine work?

In vitro effects on cells can be observed within 24 hours. In vivo, effects on tumor growth in animal models typically require several weeks of consistent administration to become apparent.

Can piperlongumine be used as a cancer treatment?

While piperlongumine shows promise in preclinical cancer models, it is not approved or validated for clinical cancer therapy in humans. Further research and clinical trials are needed before it can be considered a treatment.

Does piperlongumine have other health benefits?

Beyond its anticancer potential, preclinical studies suggest potential vascular benefits through the improvement of endothelial progenitor cell function. However, these findings require further investigation and human validation.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC12096482/ – This preclinical animal study investigated piperlongumine's effect on lung cancer. It found that piperlongumine significantly reduced tumor volume and decreased M2 macrophage polarization in a mouse xenograft model, attributing these effects to the induction of ER stress. The study provides strong preclinical evidence for piperlongumine's anticancer properties.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.689880/full – This study, combining in vitro and in vivo mouse models, demonstrated that low-dose piperlongumine could rescue impaired endothelial progenitor cell (EPC) function. It showed dose-dependent improvements in EPC migration and angiogenic function, along with reduced thrombospondin expression, suggesting potential vascular protective effects. The research highlights a novel benefit beyond anticancer activity.
https://pubmed.ncbi.nlm.nih.gov/38593312/ – This systematic review summarizes the current understanding of piperlongumine and its derivatives against cancer. It confirms their potent anticancer effects and diverse molecular targets, highlighting the need for clinical translation. The review provides a comprehensive overview of preclinical findings but emphasizes the lack of clinical trial data.